Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 11 of 11 results for canakinumab

  1. Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (TA302)

    NICE is unable to make a recommendation about the use in the NHS of canakinumab drug name (Ilaris) for systemic juvenile idiopathic arthritis..

    Technology appraisal guidance
    Published
    27 November 2013

    Sections for TA302

  2. Canakinumab for untreated Schnitzler syndrome [ID4063]

    Suggested remit: To appraise the clinical and cost effectiveness of canakinumab within its marketing authorisation for treating Schnitzler syndrome. ...

    Technology appraisal guidance
    Topic selection

  3. Canakinumab and tocilizumab for treating systemic juvenile idiopathic arthritis [ID983]

    Discontinued [GID-TA11241]

    Technology appraisal guidance
    Discontinued

  4. Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)

    Discontinued [GID-TA10337]

    Technology appraisal guidance
    Discontinued

  5. Canakinumab with pembrolizumab and chemotherapy for untreated advanced non-small cell lung cancer with no EGFR or ALK mutations [ID3977]

    Discontinued [GID-TA10857]

    Technology appraisal guidance
    Discontinued

  6. Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]

    In development [GID-TA11026] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Anakinra for treating Still's disease (TA685)

    Evidence-based recommendations on anakinra (Kineret) for treating adult-onset Still’s disease and systemic juvenile idiopathic arthritis in people 8 months and older.

    Technology appraisal guidance
    Published
    31 March 2021
    View recommendations

    Sections for TA685

  8. Gout: diagnosis and management (NG219)

    This guideline covers the diagnosis and management of gout. It includes recommendations on diagnosing gout, managing flares, long-term management of gout and referral to specialist services.

    NICE guideline
    Published
    9 June 2022
    View recommendations

    Sections for NG219

  9. Gouty arthritis: canakinumab (ESNM23)

    This advice has been updated and replaced by NICE guideline NG219.

    Evidence summary
    Published
    23 July 2013

  10. Systemic juvenile idiopathic arthritis: canakinumab (ESNM36)

    This evidence summary has been withdrawn. An NHS England clinical commissioning policy statement on biologic therapies for the treatment of juvenile idiopathic arthritis is available.

    Evidence summary
    Published
    18 March 2014

  11. Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal) (TA281)

    This guidance has been updated and replaced by NICE guideline NG219.

    Technology appraisal guidance
    Published
    24 April 2013